Tumors Resistant to EGFR Inhibitors Can Arise via Different Mechanisms

Cancer Discovery- United States

doi 10.1158/2159-8290.cd-rw2016-023

Full Text

Abstract

Available in

Date

February 11, 2016

Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

English

P2.13-21 MET Addiction Can Be Circumvented Through EGFR Inhibition via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX.

Journal of Thoracic Oncology

English

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

Molecular Cancer Therapeutics

Cancer Research

Oncology

2016

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

Oncology

2015

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

English

Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-independent and Calcium-Mediated Repression of SKP2 Transcription

Cancer Research

Oncology

2019

English

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

Cancer Research

Oncology

2011

English

Influenza Viruses Resistant to Neuraminidase Inhibitors.

Acta Biochimica Polonica

English

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors

Laboratory Investigation

English

Amanote Research

Tumors Resistant to EGFR Inhibitors Can Arise via Different Mechanisms

Cancer Discovery- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

P2.13-21 MET Addiction Can Be Circumvented Through EGFR Inhibition via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX.

Acquired Resistance Mechanisms to Combination Met-Tki/Egfr-Tki Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-independent and Calcium-Mediated Repression of SKP2 Transcription

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

Influenza Viruses Resistant to Neuraminidase Inhibitors.

WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors